BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31591454)

  • 1. United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015.
    Butler SS; Loeb S; Cole AP; Zaslowe-Dude C; Muralidhar V; Kim DW; Schaeffer EM; Trinh QD; Nguyen PL; Mahal BA
    Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):179-183. PubMed ID: 31591454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable-risk prostate cancer.
    Huang D; Ruan X; Huang J; Zhang N; Jiang G; Gao Y; Xu D; Na R
    Cancer Med; 2023 Apr; 12(8):9868-9878. PubMed ID: 36727535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations.
    Jeong CW; Washington SL; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
    Eur Urol; 2020 Sep; 78(3):335-344. PubMed ID: 31980309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.
    Mahal AR; Butler S; Franco I; Muralidhar V; Larios D; Pike LRG; Zhao SG; Sanford NN; Dess RT; Feng FY; D'Amico AV; Spratt DE; Yu JB; Nguyen PL; Rebbeck TR; Mahal BA
    Cancer; 2019 Oct; 125(19):3338-3346. PubMed ID: 31251398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
    Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
    JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
    Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
    J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
    Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
    Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
    Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.
    Moschini M; Fossati N; Sood A; Lee JK; Sammon J; Sun M; Pucheril D; Dalela D; Montorsi F; Karnes RJ; Briganti A; Trinh QD; Menon M; Abdollah F
    Eur Urol Focus; 2018 Jan; 4(1):68-74. PubMed ID: 28753764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
    Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J
    Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015.
    Mahal BA; Butler S; Franco I; Spratt DE; Rebbeck TR; D'Amico AV; Nguyen PL
    JAMA; 2019 Feb; 321(7):704-706. PubMed ID: 30743264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, Predictors, and Implications for Appropriate Use of Active Surveillance Management Among Black Men Diagnosed With Low-risk Prostate Cancer.
    Taku N; Narayan V; Wang X; Vapiwala N
    Am J Clin Oncol; 2019 Jun; 42(6):507-511. PubMed ID: 31045876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
    Herden J; Weissbach L
    World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Egger SJ; Calopedos RJ; O'Connell DL; Chambers SK; Woo HH; Smith DP
    Eur Urol; 2018 Jun; 73(6):859-867. PubMed ID: 28851582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States.
    Al Hussein Al Awamlh B; Wu X; Barocas DA; Moses KA; Hoffman RM; Basourakos SP; Lewicki P; Smelser WW; Arenas-Gallo C; Shoag JE
    Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):395-402. PubMed ID: 35882950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study.
    Bandini M; Nazzani S; Marchioni M; Preisser F; Tian Z; Moschini M; Abdollah F; Suardi N; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2019 Feb; 17(1):72-78.e4. PubMed ID: 30342845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison of survival between active surveillance or watchful waiting and focal therapy for low-risk prostate cancer: a real-world study from the SEER database.
    Yuan QM; Lin TH; Jin K; Qiu S; Zhou XH; Jin D; Li JK; Yang L; Wei Q
    Asian J Androl; 2022; 24(3):305-310. PubMed ID: 34596600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Sociodemographic Factors on Definitive Intervention Among Low-risk Active Surveillance Patients.
    Sayyid RK; Klotz L; Benton JZ; Lodh A; Lambert JH; Woodruff P; Lokeshwar SD; Madi R; Goldberg H; Terris MK; Wallis CJD; Klaassen Z
    Urology; 2021 Sep; 155():117-123. PubMed ID: 33577898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States.
    Al Hussein Al Awamlh B; Ballman KV; Ma X; Hu JC; Shoag JE
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):714-717. PubMed ID: 32661433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.